Idecabtagene Vicleucel (ide-cel) versus Standard (std) Regimens in Patients (pts) with Triple-class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

被引：0

作者：

Scheid, Christoph ^{[1
]}

Rodriguez-Otero, Paula ^{[2
]}

Ailawadhi, Sikander ^{[3
]}

Arnulf, Bertrand ^{[4
]}

Patel, Krina ^{[5
]}

Cavo, Michele ^{[6
]}

Nooka, Ajay K. ^{[7
]}

Manier, Salomon ^{[8
]}

Callander, Natalie ^{[9
]}

Costa, Luciano J. ^{[10
]}

Vij, Ravi ^{[11
]}

Bahlis, Nizar J. ^{[12
]}

Moreau, Philippe ^{[13
]}

Solomon, Scott R. ^{[14
]}

Abrahamsen, Ingerid Weum ^{[15
]}

Baz, Rachid ^{[16
]}

Broijl, Annemiek ^{[17
]}

Chen, Christine ^{[18
]}

Jagannath, Sundar ^{[19
]}

Raje, Noopur ^{[20
]}

Delforge, Michel ^{[21
]}

Benjamin, Reuben ^{[22
]}

Pabst, Thomas ^{[23
]}

Iida, Shinsuke ^{[24
]}

Berdeja, Jesus ^{[25
]}

Truppel-Hartmann, Anna ^{[26
]}

Bhatnagar, Rashmi ^{[27
]}

Wu, Fan ^{[28
]}

Piasecki, Julia ^{[28
]}

Eliason, Laurie ^{[28
]}

Dhanda, Devender ^{[28
]}

Felten, Jasper ^{[28
]}

Caia, Andrea ^{[28
]}

Cook, Mark ^{[29
]}

Mckiver, Mihaela Popa ^{[28
]}

Giralt, Sergio ^{[30
]}

机构：

[1] Univ Cologne, Cologne, Germany

[2] Clin Univ Navarra, Pamplona, Spain

[3] Mayo Clin, Jacksonville, FL USA

[4] Univ Paris Cite, Paris, France

[5] Univ Texas Houston, Houston, TX USA

[6] Bologna Univ, Sch Med, Bologna, Italy

[7] Emory Univ, Atlanta, GA USA

[8] Univ Lille, Lille, France

[9] Univ Wisconsin, Madison, WI USA

[10] Univ Alabama Birmingham, Birmingham, AL USA

[11] Washington Univ, Sch Med St Louis, St Louis, MO USA

[12] Univ Calgary, Calgary, AB, Canada

[13] Univ Hosp Nantes, Nantes, France

[14] Northside Hosp Canc Inst, Atlanta, GA USA

[15] Oslo Univ Hosp, Oslo, Norway

[16] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[17] Erasmus MC Canc Inst, Rotterdam, Netherlands

[18] Princess Margaret Hosp, Toronto, ON, Canada

[19] Mt Sinai Med Ctr, New York, NY USA

[20] Massachusetts Gen Hosp, Boston, MA USA

[21] Univ Ziekenhuizen Leuven, Leuven, Belgium

[22] Kings Coll Hosp London, London, England

[23] Bern Univ Hosp, Bern, Switzerland

[24] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan

[25] Sarah Cannon Res Inst, Nashville, TN USA

[26] 2seventy Bio, Cambridge, MA USA

[27] Syneos Hlth, Gurugram, Haryana, India

[28] Bristol Myers Squibb, Princeton, NJ USA

[29] Bristol Myers Squibb, Boudry, Switzerland

[30] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1060

引用

页码：247 / 248

页数：2

共 50 条

[21] Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial
Delforge, Michel
Patel, Krina K.
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas S.
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie S.
Giralt, Sergio A.
Einsele, Hermann
Ailawadhi, Sikander
Popa-McKiver, Mihaela
Cook, Mark
Otero, Paula Rodriguez
BLOOD, 2023, 142
[22] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
Mancuso, Katia
Barbato, Simona
Talarico, Marco
Tacchetti, Paola
Zamagni, Elena
Cavo, Michele
EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
[23] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
Einsele, Hermann
Berdeja, Jesus
Raje, Noopur
Siegel, David
Lin, Yi
Anderson, Larry, Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy
Jagannath, Sundar
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
[24] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
Einsele, H.
Berdeja, J.
Raje, N. S.
Siegel, D. S.
Lin, Y.
Anderson, L. D., Jr.
Rodriguez-Otero, P.
Manier, S.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Sanford, J.
Wang, J.
Campbell, T. B.
Jagannath, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
[25] Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews
Rodriguez Otero, Paula
Patel, Krina K.
Raje, Noopur S.
Moshkovich, Olga
Gerould, Heather
Devlen, Jennifer
Dhanda, Devender
Eliason, Laurie
Cook, Mark
Popa-McKiver, Mihaela
Manier, Salomon
BLOOD, 2023, 142
[26] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
Einsele, H.
Raab, M.
Kroeger, N.
Fenk, R.
Scheid, C.
Munshi, N.
Petrocca, F.
Hege, K.
Novick, S.
Raje, N.
Kochenderfer, J. N.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
[27] Effects of Idecabtagene Vicleucel ( Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial
Delforge, Michel
Patel, Krina K.
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas S.
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie S.
Giralt, Sergio A.
Einsele, Hermann
Ailawadhi, Sikander
Popa-McKiver, Mihaela
Cook, Mark
Otero, Paula Rodriguez
BLOOD, 2023, 142
[28] KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)
Einsele, H.
Kansagra, A.
Lin, Y.
Berdeja, J.
Shah, N.
Oriol, A.
Yakoub-Agha, I
Rambaldi, A.
Truppel-Hartmann, A.
Rowe, E.
Wang, J.
Agarwal, A.
Campbell, T. B.
Lonial, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 208 - 209
[29] Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Rodriguez-Otero, Paula
Ailawadhi, Sikander
Arnulf, Bertrand
Patel, Krina
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie
Costa, Luciano J.
Vij, Ravi
Bahlis, Nizar J.
Moreau, Philippe
Solomon, Scott R.
Delforge, Michel
Berdeja, Jesus
Truppel-Hartmann, Anna
Yang, Zhihong
Favre-Kontula, Linda
Wu, Fan
Piasecki, Julia
Cook, Mark
Giralt, Sergio
FUTURE ONCOLOGY, 2024, 20 (18) : 1221 - 1235
[30] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
Cavo, M.
Oriol, A.
San-Miguel, J.
Kansagra, A.
Madduri, D.
Shah, N.
Moreau, P.
Yakoub-Agha, I.
Delforge, M.
Einsele, H.
Goldschmidt, H.
Weisel, K.
Rambaldi, A.
Reece, D.
Rodriguez-Otero, P.
Petrocca, F.
Connarn, J.
Patel, P.
Huang, L.
Campbell, T.
Hege, K.
Munshi, N.
HAEMATOLOGICA, 2021, 106 (10) : 5 - 5

← 1 2 3 4 5 →